Design Therapeutics Inc. (NASDAQ: DSGN) stock jumped 10.68% on Wednesday to $17.52 against a previous-day closing price of $15.83. With 0.76 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.26 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $18.02 whereas the lowest price it dropped to was $15.59. The 52-week range on DSGN shows that it touched its highest point at $26.30 and its lowest point at $9.61 during that stretch. It currently has a 1-year price target of $26.80.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of DSGN was up-trending over the past week, with a rise of 14.73%, but this was down by -13.65% over a month. Three-month performance surged to 24.96% while six-month performance rose 6.31%. The stock gained 21.84% in the past year, while it has lost -18.17% so far this year. A look at the trailing 12-month EPS for DSGN yields -0.91 with Next year EPS estimates of -1.45. For the next quarter, that number is -0.29. This implies an EPS growth rate of -402.80% for this year and -31.80% for next year.
Float and Shares Shorts:
At present, 55.67 million DSGN shares are outstanding with a float of 35.26 million shares on hand for trading. On Jul 14, 2022, short shares totaled 4.22 million, which was 7.56% higher than short shares on Jun 14, 2022. In addition to Dr. João Siffert M.D. as the firm’s Pres, CEO & Director, Dr. Sean Jeffries Ph.D. serves as its Chief Operating Officer.
Through their ownership of 68.47% of DSGN’s outstanding shares, institutional investors have majority control over the company. Other institutions hold 44.02% of DSGN, in contrast to 14.83% held by mutual funds. Shares owned by individuals account for 12.44%. As the largest shareholder in DSGN with 9.86% of the stake, Cormorant Asset Management LP holds 5,500,000 shares worth 5,500,000. A second-largest stockholder of DSGN, Logos Global Management LP, holds 2,797,501 shares, controlling over 5.01% of the firm’s shares. Ecor1 Capital LLC is the third largest shareholder in DSGN, holding 2,634,178 shares or 4.72% stake. With a 1.84% stake in DSGN, the Fidelity Select Port. – Biotechno is the largest stakeholder. A total of 1,024,935 shares are owned by the mutual fund manager. The BlackRock Health Sciences Trust I, which owns about 1.51% of DSGN stock, is the second-largest Mutual Fund holder. It holds 841,761 shares valued at 17.05 million. iShares Russell 2000 ETF holds 1.26% of the stake in DSGN, owning 705,437 shares worth 14.29 million.
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for DSGN since 5 analysts follow the stock currently. There are 4 analysts who recommend BUY ratings, while 1 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With DSGN analysts setting a high price target of $42.00 and a low target of $6.00, the average target price over the next 12 months is $26.80. Based on these targets, DSGN could surge 139.73% to reach the target high and fall by -65.75% to reach the target low. Reaching the average price target will result in a growth of 52.97% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. DSGN will report FY 2022 earnings on 03/09/2023. Analysts have provided yearly estimates in a range of -$1.08 being high and -$1.13 being low. For DSGN, this leads to a yearly average estimate of -$1.10. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Design Therapeutics Inc. surprised analysts by -$0.02 when it reported -$0.27 EPS against a consensus estimate of -$0.25. The surprise factor in the prior quarter was -$0.02. Based on analyst estimates, the high estimate for the next quarter is -$0.27 and the low estimate is -$0.31. The average estimate for the next quarter is thus -$0.29.
Summary of Insider Activity:
Insiders traded DSGN stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has increased to 2 while that of sell transactions has risen to 4 over the past year. The total number of shares bought during that period was 36,806 while 590,880 shares were sold.